Regulatory Considerations of Orthobiologic Procedures

Area of Science:

• Orthopedics
• Regenerative Medicine
• Biologics Therapy

Background:

• Biologic injections for musculoskeletal conditions are rapidly advancing.
• Concerns exist regarding unverified and unsafe applications of these therapies.
• Regulatory oversight is crucial for ensuring product safety and efficacy.

Purpose of the Study:

• To outline current Food and Drug Administration (FDA) regulations for commonly used biologic products.
• To inform clinicians about the evolving regulatory landscape for biologics.
• To ensure adherence to federal guidelines for safe and effective use.

Main Methods:

• Review of current FDA regulations pertaining to biologic products.
• Description of regulatory requirements for platelet-rich plasma (PRP).
• Explanation of regulations for bone marrow aspirate concentrate (BMAC), adipose-derived products, and birth tissue products.

Main Results:

• The FDA mandates specific regulations for biologic products used in musculoskeletal treatments.
• Regulations vary in stringency based on the product type and its intended use.
• Continuous updates to federal enforcement require ongoing clinician awareness.

Conclusions:

• Staying informed about FDA regulations is essential for clinicians using biologic therapies.
• Compliance with regulatory standards ensures patient safety and treatment efficacy.
• This article provides a guide to the current regulatory framework for key biologic products.